Becton Dickinson & Co Stock Price, News & Analysis

BD (NYSE: BDX), a leading global medical technology company, announced its upcoming presentation at the 7th Annual Evercore ISI HealthCONx Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 10:50 am Eastern Time.

Interested parties can access the live webcast through BD's investor relations website at investors.bd.com. A replay will be made available on the same webpage after the presentation concludes.

BD (BDX) reported strong Q4 and FY2024 results with Q4 revenue reaching $5.4 billion, up 6.9% as reported. Fourth quarter GAAP and adjusted diluted EPS from continuing operations grew 173.6% and 11.4% to $1.45 and $3.81 respectively. Full-year revenue reached $20.2 billion, with organic growth of 5.0%. FY2024 cash from continuing operations increased 28.5% to $3.8 billion, while Free Cash Flow grew 47.4% to $3.1 billion. The company provided FY2025 guidance projecting organic growth of 4.0% to 4.5% and adjusted diluted EPS growth of approximately 10% at midpoint.

BD (NYSE: BDX) has announced a 9.5% increase in its quarterly dividend to $1.04 per common share, payable on December 31, 2024, to shareholders of record on December 9, 2024. This marks the company's 53rd consecutive year of dividend increases, maintaining its position in the S&P 500 Dividend Aristocrats Index. The indicated annual dividend rate for fiscal year 2025 is set at $4.16 per share. Management attributes this increase to confidence in their long-term outlook and commitment to shareholder value through their BD 2025 strategy.

BD (NYSE: BDX) has launched the new BD® Intraosseous Vascular Access System, designed for rapid delivery of fluids or medication in emergency situations where IV access is challenging. The system features unique advantages including placement capability after extension set attachment and integrated passive needle tip safety. The device offers five needle length options and includes a rechargeable battery that lasts up to 12 times longer than competitors'. Clinical studies show trained users achieve a 93-97% success rate in IO placement, with less than 1% chance of serious complications. The system is now available in the U.S. market.

BD (NYSE: BDX) has been recognized among the 100 Best Corporate Citizens of 2024 by 3BL, securing the second position in the healthcare equipment and services industry for the second consecutive year. The ranking evaluates 1,000 largest U.S. public companies based on over 200 factors across seven pillars including climate change, employee relations, environment, governance, human rights, and stakeholders and society.

Chairman, CEO and president Tom Polen emphasized that corporate sustainability is integrated into BD's business strategy and influences their healthcare-focused decision-making process.

BD (NYSE: BDX) has launched a new high-throughput, robotics-compatible reagent kit for automating single-cell discovery studies. The solution includes the BD® OMICS-One XT WTA Assay and the Hamilton® Microlab™ NGS STAR automated liquid handling platform. This collaboration aims to standardize manual processes and accelerate genetic sequencing material generation.

The automation addresses challenges in DNA library preparation, such as variability, compromised data quality, throughput, high costs, and long turnaround times. It offers increased consistency, efficiency, and reproducibility in experiments, particularly beneficial for oncology and immunology research.

The BD® OMICS-One XT Library Preparation Reagent Kits and Hamilton Microlab NGS STAR platform are now commercially available worldwide.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has announced that it will report its fiscal 2024 fourth quarter and full year financial results on Thursday, Nov. 7, 2024. A news release will be issued at approximately 6:30 a.m. ET, with related presentation materials available on the company's investor relations website.

BD management will host an audio webcast at 8 a.m. ET on the same day to discuss the financial results and provide updates on operations and strategy. The company has also announced dates for its fiscal 2025 quarterly earnings webcasts, which are scheduled for February 6, May 1, July 31, and November 6, 2025.

BD (NYSE: BDX) has reached an agreement to resolve the majority of its existing hernia litigation, including cases in Rhode Island and Ohio. The settlement amount, which is confidential, falls within the company's current product litigation reserve and will be paid over multiple years. This agreement is structured to eliminate uncertainty for all stakeholders related to the settled cases.

Key points:

• No admission of liability or wrongdoing by BD
• Settlement will not impact BD's cash flow goals or capital allocation strategy
• No incremental charge to BD's consolidated income statement
• BD will continue to defend itself in unresolved cases

BD emphasizes its commitment to patient safety and product quality, acknowledging that all implantable medical devices carry inherent risks and benefits.

BD (NYSE: BDX) announced new data highlighting the effectiveness of its artificial intelligence technology in detecting controlled substance diversion in hospital operating rooms. A study conducted at an Ochsner Health medical center, published in the American Journal of Health-System Pharmacy, showed that BD HealthSight™ Diversion Management software can identify blind spots in medication movement undetected by manual processes.

Key findings include:

• 55% increase in charting discrepancies detected
• 14% increase in incidents resolved by operating room analysts
• 10% decrease in cases requiring additional documentation
• Reduction in auditor review time from 3 business days to 50 minutes

The study emphasizes the importance of advanced analytics in combating drug diversion, a persistent issue in healthcare settings.